UCBUCBJF 91 Net Margin % is 25.46% as of Dec. 2025, which is 56% above its 10-year median of 16.37. GuruFocus rates UCBJF with a GF Score™ of 91/100 and a GF Value™ of $262.49 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 946 Biotechnology companies, UCB ranks better than 87.63% on this metric.
Net margin is calculated as Net Income divided by its Revenue. UCB's Net Income for the
six
months ended in Dec. 2025 was $1,268 Mil. UCB's Revenue for the
six
months ended in Dec. 2025 was $4,981 Mil. Therefore, UCB's net margin for the quarter that ended in Dec. 2025 was 25.46%.
The historical rank and industry rank for UCB's Net Margin % or its related term are showing as below:
UCBJF'
s Net Margin % Range Over the Past 10 Years
Min: 6.53 Med: 16.37 Max: 20.13
Current: 20.13
UCBJF's Net Margin % is ranked better than 87.63% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs UCBJF: 20.13
UCB (OTCPK:UCBJF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
UCB Net Margin % Related Terms
UCB Net Margin % Historical Data
* Premium members only.
The historical data trend for UCB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCBJF vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, UCB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's Net Margin % distribution charts can be found below:
* The bar in red indicates where UCB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB (UCBJF) has a Net Margin % of 25.46% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on UCB and its competitors. This is 56% above median its historical median of 16.37. Over the past decade, UCB's Net Margin % has ranged from 6.53 to 20.13. According to the industry distribution chart, UCB ranks #117 out of 946 companies in the Biotechnology industry, placing it in the top 12.4%.
Is UCB's Net Margin % too high?
UCB's current Net Margin % of 25.46% is 56% above median its 10-year median of 16.37. Over the past 10 years, this metric has ranged from a low of 6.53 to a high of 20.13. Based on the distribution chart, UCB ranks #117 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UCB has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #117 out of 946 companies for Net Margin %. This places UCB in the top 12% of its industry — outperforming the majority of peers. Historically, UCB's own Net Margin % has ranged from 6.53 to 20.13 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on UCB and its competitors. UCB's current Net Margin % is 25.46%, which is 56% above median its own 10-year median of 16.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (UCBJF) is currently considered Modestly Overvalued. The stock's GF Value™ is $262.49, compared to a current price of $296.74 — trading 13% above its estimated fair value. The current Net Margin % is 25.46%, which is 56% above median its 10-year median of 16.37. UCB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For UCB (UCBJF), the current Net Margin % is 25.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (UCBJF) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be overvalued.
The current stock price of $296.74 is trading 13% above its estimated GF Value™ of $262.49.
GuruFocus considers UCB to be Modestly Overvalued.
Key valuation signals for UCBJF:
Net Margin %: 25.46% (56% above median its 10-year median of 16.37)
GF Value™: $262.49 vs. price of $296.74 (13% above fair value)
No single metric tells the full story. See the UCBJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
91GF Score
Get the complete analysis for UCBJF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UCBJF has been successfully added to your 
